VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding
Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.
Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.
Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.
A pediatric dosing tool developed by the World Health Organization might assist in the design of clinical trials for dosing in children.
If you're a provider, you want to offer patients the latest, evidence-based ways to reduce their risk for HIV -- including women who may have increased risk because of the microbes in their genital tracts.
"Even if we have the best drug, it cannot do anything if we don't have all [the social] aspects together," says Bindiya Meggi, M.Sc.
"Look for women mentors and make use of the spaces we have created for you," says Morenike Ukpong-Folayan.
Women with HIV tend to perform worse than HIV-negative women on cognitive performance tests, even after many years on treatment, new research finds -- but trends differed depending on the test and on women's treatment success.
Dolutegravir granules-in-suspension achieved satisfactory exposures in children aged between 2 and 6 years, according to data presented at CROI2017.
The U.S. Centers for Disease Control and Prevention has released new data on the estimated number of annual HIV infections nationally, by transmission route and by state from 2008-2014 in the United States.